Tuesday, January 26, 2010

DDP 2010: Passport® Transdermal System: Developing Biobetters with a Transdermal Technology for Biological Drugs and Vaccines

Eric Tomlinson, PhD
Chief Executive Officer
Altea Therapeutics

Transdermal, one normally thinks that the drug is delivered by a patch to the skin. Altea has found clinically proven transdermal delivery technology for water-soluble small drugs, biological and vaccines.

Why have a transdermal patch?
-Painless delivery
-High patient compliance
-Improved safety
-Life cycle management
-Expedited regulatory patch

The skin is all dead cells, and they’re interspersed with lipids. The outside layer is the barrier for transdermal delivery other than small transdermal drugs. They work to create subtle channels to introduce the drugs into the skin.

The PassPort® System painlessly creates microscopic channels in the dead outer layer and positions a transdermal patch over the channels. The removal of the outer layer of the skin creates channels to mass transfer drugs. They can be up to 12 square centimeters. The PassPort® has dose reminder features.

Delivery capabilities: 3 Features of a drug: Molecular size (300 kDa), Aqueous solubility (300 mg/mL), Dose achieved per single application.

Patient benefits include high patient compliance with transdermal patches and broad application to water-soluble drugs.

Share this article with your social network, just click below to share now!

No comments :

Post a Comment